{"disease":{"id":"coronary-disease","name":"coronary disease"},"drugs":{"marketed":[{"drug_id":"atorvastatin","indication_name":"Primary Prevention of Coronary Heart Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"atorvastatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":77,"revenue":"1000.0","mechanism":"Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis."},{"drug_id":"atorvastatin","indication_name":"Slow Progression of Coronary Artery Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"atorvastatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":77,"revenue":"1000.0","mechanism":"Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis."},{"drug_id":"inositol","indication_name":"Slow Progression of Coronary Artery Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inosital","generic_name":"INOSITOL","company_name":"","drug_phase":"discontinued","molecular_target":"","drug_class":"inositol","quality_score":null,"revenue":null,"mechanism":"Inosital works by influencing the metabolism of lipids in the body."},{"drug_id":"fludeoxyglucose","indication_name":"coronary artery disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludeoxyglucose F-18","generic_name":"FLUDEOXYGLUCOSE","company_name":"Downstate Clincl","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":44,"revenue":null,"mechanism":"Fludeoxyglucose F-18 is a radioactive sugar molecule that accumulates in cells with high metabolic activity, allowing for visualization of cancer and other conditions."},{"drug_id":"fludeoxyglucose","indication_name":"coronary artery disease and left ventricular dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludeoxyglucose F-18","generic_name":"FLUDEOXYGLUCOSE","company_name":"Downstate Clincl","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":44,"revenue":null,"mechanism":"Fludeoxyglucose F-18 is a radioactive sugar molecule that accumulates in cells with high metabolic activity, allowing for visualization of cancer and other conditions."},{"drug_id":"f-18","indication_name":"coronary artery disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludeoxyglucose F-18","generic_name":"F-18","company_name":"3D Imaging Drug","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":44,"revenue":null,"mechanism":"Fludeoxyglucose F-18 is a radioactive molecule that accumulates in areas of high metabolic activity, allowing for imaging of various conditions."},{"drug_id":"f-18","indication_name":"coronary artery disease and left ventricular dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludeoxyglucose F-18","generic_name":"F-18","company_name":"3D Imaging Drug","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":44,"revenue":null,"mechanism":"Fludeoxyglucose F-18 is a radioactive molecule that accumulates in areas of high metabolic activity, allowing for imaging of various conditions."},{"drug_id":"fluvastatin","indication_name":"Slow Progression of Coronary Artery Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lescol","generic_name":"FLUVASTATIN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":65,"revenue":null,"mechanism":"Fluvastatin sodium inhibits HMG-CoA reductase, reducing cholesterol biosynthesis and increasing LDL receptor activity, lowering plasma cholesterol."},{"drug_id":"lopid","indication_name":"Reducing risk of developing coronary heart disease in Type IIb patients without history or symptoms of existing coronary heart disease with low HDL-cholesterol, elevated LDL-cholesterol, and elevated triglycerides unresponsive to weight loss, diet, exercise, and other pharmacologic agents","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lopid","generic_name":"Gemfibrozil","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"PPAR-alpha (Peroxisome Proliferator-Activated Receptor Alpha)","drug_class":"Peroxisome Proliferator Receptor alpha Agonist [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"non-interventional-study","indication_name":"Coronary Artery Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"simvastatin","indication_name":"Slow Progression of Coronary Artery Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zocor","generic_name":"simvastatin","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"telmisartan","indication_name":"History of myocardial infarction due to atherothrombotic coronary artery disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Micardis","generic_name":"TELMISARTAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Type-2 angiotensin II receptor","drug_class":"Angiotensin 2 Receptor Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Micardis works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure."},{"drug_id":"nitroglycerin","indication_name":"Acute relief of angina pectoris due to coronary artery disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NITROGLYCERIN","company_name":"","drug_phase":"marketed","molecular_target":"Nitric oxide synthase pathway","drug_class":"Nitrate Vasodilator [EPC]","quality_score":10,"revenue":null,"mechanism":"Nitroglycerin forms nitric oxide, which activates guanylate cyclase, leading to increased cyclic GMP and subsequent vasodilation in smooth muscle."},{"drug_id":"myoinositol","indication_name":"Slow Progression of Coronary Artery Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Myoinositol","company_name":"University of Colorado, Denver","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"gemfibrozil","indication_name":"Primary Prevention of Coronary Heart Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lopid","generic_name":"GEMFIBROZIL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"Peroxisome Proliferator Receptor alpha Agonist [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"fenofibrate","indication_name":"At increased risk of coronary heart disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tricor (Micronized)","generic_name":"FENOFIBRATE","company_name":"Salix","drug_phase":"marketed","molecular_target":"PPARα","drug_class":"Peroxisome Proliferator Receptor alpha Agonist [EPC]","quality_score":80,"revenue":null,"mechanism":"Fenofibrate activates PPARα, enhancing lipolysis and reducing triglycerides, while increasing HDL-cholesterol and uric acid excretion."},{"drug_id":"rosuvastatin","indication_name":"Primary Prevention of Coronary Heart Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crestor","generic_name":"rosuvastatin","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":74,"revenue":null,"mechanism":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor."},{"drug_id":"lipitor","indication_name":"Primary Prevention of Coronary Heart Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"Atorvastatin Calcium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"atorvastatin","quality_score":10,"revenue":null,"mechanism":"Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis."},{"drug_id":"lipitor","indication_name":"Slow Progression of Coronary Artery Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"Atorvastatin Calcium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"atorvastatin","quality_score":10,"revenue":null,"mechanism":"Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis."},{"drug_id":"technetium","indication_name":"coronary artery disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Technetium Tc 99M Sestamibi","generic_name":"TECHNETIUM","company_name":"Cyclomedica","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":44,"revenue":null,"mechanism":"Technetium Tc 99m Sestamibi accumulates in viable myocardial tissue similar to thallous chloride TI-201, with possible mitochondrial retention."},{"drug_id":"technetium","indication_name":"coronary artery disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Technetium Tc 99M Sestamibi","generic_name":"TECHNETIUM","company_name":"Cyclomedica","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":44,"revenue":null,"mechanism":"Technetium Tc 99m Sestamibi accumulates in viable myocardial tissue similar to thallous chloride TI-201, with possible mitochondrial retention."},{"drug_id":"flurpiridaz","indication_name":"coronary artery disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flyrcado","generic_name":"FLURPIRIDAZ","company_name":"Ge Hlthcare","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":55,"revenue":null,"mechanism":"Flyrcado emits radiation to create detailed images of the heart, allowing for the diagnosis of coronary artery disease and other heart conditions."},{"drug_id":"ppsv23","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae in adults 2 years of age or older with chronic heart disease, including congestive heart failure, coronary artery disease, or cardiac transplantation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ppsv23","generic_name":"ppsv23","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"amlodipine","indication_name":"Primary Prevention of Coronary Heart Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norvasc","generic_name":"amlodipine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6","drug_class":"Calcium channel blocker (dihydropyridine)","quality_score":55,"revenue":null,"mechanism":"Long-acting dihydropyridine calcium channel blocker that relaxes vascular smooth muscle, reducing blood pressure and myocardial oxygen demand."},{"drug_id":"lovastatin","indication_name":"Primary Prevention of Coronary Heart Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mevacor","generic_name":"LOVASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":null,"revenue":null,"mechanism":"Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver."},{"drug_id":"lovastatin","indication_name":"Slow Progression of Coronary Artery Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mevacor","generic_name":"LOVASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":null,"revenue":null,"mechanism":"Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver."},{"drug_id":"pritor","indication_name":"History of myocardial infarction due to atherothrombotic coronary artery disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pritor","company_name":"DongKoo Bio & Pharma","drug_phase":"phase_1","molecular_target":"ATP-binding cassette sub-family G member 2, Multidrug and toxin extrusion protein 1, Type-2 angiotensin II receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"caduet","indication_name":"Coronary Artery Disease (CAD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caduet","generic_name":"Amlodipine Besylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channel","drug_class":"Dihydropyridine calcium channel blocker","quality_score":76,"revenue":null,"mechanism":"Calcium channel antagonist inhibiting transmembrane calcium influx into vascular and cardiac muscle."},{"drug_id":"amlodipin","indication_name":"Primary Prevention of Coronary Heart Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amlodipin","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"caduet","indication_name":"Multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caduet","generic_name":"Amlodipine Besylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channel","drug_class":"Dihydropyridine calcium channel blocker","quality_score":76,"revenue":null,"mechanism":"Calcium channel antagonist inhibiting transmembrane calcium influx into vascular and cardiac muscle."}],"pipeline":[],"offLabel":[],"totalMarketed":30,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05198492","title":"Short- and Long-term Health Effects of Air Pollution in Poland","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8300000,"lead_sponsor_name":"Medical University of Bialystok","has_results":false},{"nct_id":"NCT04834843","title":"Temporal Trends of COronary Artery Disease and PEripheral Artery Disease (COPE) in Korea","phase":"","overall_status":"COMPLETED","enrollment_count":700000,"lead_sponsor_name":"Wonju Severance Christian Hospital","has_results":false},{"nct_id":"NCT07442500","title":"Drug Coated Balloon vs. Drug-eluting Stent in Patients With Coronary Artery Disease","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":470000,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT02550717","title":"Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN)","phase":"","overall_status":"COMPLETED","enrollment_count":398158,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04715594","title":"CONNECT DES Registrty","phase":"","overall_status":"UNKNOWN","enrollment_count":350000,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT04778969","title":"Kor PCI - CAD Patients Treated With PCI: Analysis of the Korean Nationwide Health Insurance Database","phase":"","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT03987633","title":"EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Future Genetics Limited","has_results":false},{"nct_id":"NCT05050877","title":"Risk Factors and Prognosis of Adverse Cardiovascular and Kidney Events After Coronary Intervention II","phase":"","overall_status":"COMPLETED","enrollment_count":184855,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT04541498","title":"Impact of Air Pollution and Climate Changes on the Epidemiology of Cardiovascular Disease","phase":"","overall_status":"COMPLETED","enrollment_count":150000,"lead_sponsor_name":"Medical University of Bialystok","has_results":false},{"nct_id":"NCT06338956","title":"Optimal Attained LDL-Cholesterol Levels in Patients Who Achieved ≥50% LDL Reduction After PCI","phase":"","overall_status":"COMPLETED","enrollment_count":135877,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT04008173","title":"The International Survey of Acute Coronary Syndromes-ARCHIVES","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":130000,"lead_sponsor_name":"University of Bologna","has_results":false},{"nct_id":"NCT06241833","title":"Emulation of Randomized Clinical Trial in Cardiovascular Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":118420,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT05337319","title":"Prospective Registry of the Current Status of Care for Patients With Coronary Artery Disease","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Beijing Anzhen Hospital","has_results":false},{"nct_id":"NCT07068490","title":"Impact of Potassium Competitive Acid Blockers After Percutaneous Coronary Intervention for Efficacy and Safety Outcome: Target Trial Emulation Study.","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT06512493","title":"South East (Zuid Oost) Netherlands Heart Registry","phase":"","overall_status":"RECRUITING","enrollment_count":99999,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT04407936","title":"Risk Factors and Prognosis of Adverse Cardiovascular and Kidney Events After Coronary Intervention","phase":"","overall_status":"COMPLETED","enrollment_count":88938,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT04597489","title":"Fractional FLOw Reserve In Cardiovascular DiseAses","phase":"","overall_status":"COMPLETED","enrollment_count":64045,"lead_sponsor_name":"LinkCare GmbH","has_results":false},{"nct_id":"NCT04196712","title":"Essen Coronary Artery Disease Registry","phase":"","overall_status":"RECRUITING","enrollment_count":55000,"lead_sponsor_name":"University Hospital, Essen","has_results":false},{"nct_id":"NCT05699629","title":"Prospective Coronary Heart Disease Cohort","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Shandong First Medical University","has_results":false},{"nct_id":"NCT04691037","title":"CCTA Improves Clinical Management of Stable Chest Pain","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Tianjin Chest Hospital","has_results":false},{"nct_id":"NCT06794684","title":"PRogression of Atheroma Evaluated by CT Angiography and IntraCoronary Imaging tEchniques","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT07063147","title":"TTE Improves Clinical Management of Stable Chest Pain","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Tianjin Chest Hospital","has_results":false},{"nct_id":"NCT04584645","title":"A Digital Flu Intervention for People With Cardiovascular Conditions","phase":"NA","overall_status":"COMPLETED","enrollment_count":49138,"lead_sponsor_name":"Evidation Health","has_results":true},{"nct_id":"NCT03934957","title":"Hamburg City Health Study - a German Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":45000,"lead_sponsor_name":"Universitätsklinikum Hamburg-Eppendorf","has_results":false},{"nct_id":"NCT05051904","title":"A Study Based on Japanese Medical Records That Looks at Bleeding Events in People With Atrial Fibrillation and Coronary Artery Disease Who Start Taking Either Dabigatran, Rivaroxaban, or Warfarin","phase":"","overall_status":"COMPLETED","enrollment_count":39357,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT01218776","title":"International Survey of Acute Coronary Syndromes","phase":"","overall_status":"RECRUITING","enrollment_count":36000,"lead_sponsor_name":"University of Bologna","has_results":false},{"nct_id":"NCT03133689","title":"Alcohol Consumption and Coronary Heart Disease Onset","phase":"","overall_status":"COMPLETED","enrollment_count":35132,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT04279496","title":"Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":35000,"lead_sponsor_name":"Cleerly, Inc.","has_results":false},{"nct_id":"NCT06459934","title":"Clinical Outcomes of Cardiovascular Disease","phase":"","overall_status":"RECRUITING","enrollment_count":30000,"lead_sponsor_name":"Xinjiang Medical University","has_results":false},{"nct_id":"NCT07149688","title":"Village-Based Management of Chronic Cardiovascular Disease in Qu Jiang Elderly Population Registry: The BOUQUET Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":30000,"lead_sponsor_name":"Beijing Anzhen Hospital","has_results":false},{"nct_id":"NCT06736626","title":"The xDAPT External Validation Study","phase":"","overall_status":"COMPLETED","enrollment_count":30000,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":false},{"nct_id":"NCT07480512","title":"Causation And Prognosis Analyses of Coronary Artery Diseases: A Longitudinal Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":30000,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03781492","title":"Stable Angina Management and Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":25000,"lead_sponsor_name":"Silesian Centre for Heart Diseases","has_results":false},{"nct_id":"NCT06001073","title":"Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics","phase":"","overall_status":"RECRUITING","enrollment_count":25000,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT04844944","title":"The Helios Heart Registry: A Standardized Registry for Patients With Specific Cardiac Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":24000,"lead_sponsor_name":"Helios Health Institute GmbH","has_results":false},{"nct_id":"NCT03180060","title":"Meta-Analysis of Stress Myocardial Perfusion Imaging","phase":"","overall_status":"COMPLETED","enrollment_count":23051,"lead_sponsor_name":"American British Cowdray Medical Center","has_results":false},{"nct_id":"NCT07202754","title":"Procedural Complications and Long-Term Mortality in Complex Coronary Interventions","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Istanbul Mehmet Akif Ersoy Educational and Training Hospital","has_results":false},{"nct_id":"NCT06376851","title":"AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20000,"lead_sponsor_name":"HeartFlow, Inc.","has_results":false},{"nct_id":"NCT06335901","title":"Clinical Characteristics and Outcomes of Coronary Heart Disease","phase":"","overall_status":"COMPLETED","enrollment_count":20000,"lead_sponsor_name":"Xinjiang Medical University","has_results":false},{"nct_id":"NCT06338761","title":"Switching to E-cigarette After PCI","phase":"","overall_status":"COMPLETED","enrollment_count":17973,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT03507205","title":"Korean Nationwide Multicenter Pooled Registry of Drug-Eluting Stents","phase":"","overall_status":"COMPLETED","enrollment_count":17286,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT05782881","title":"High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention Program","phase":"NA","overall_status":"UNKNOWN","enrollment_count":16000,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT03338335","title":"Ethnic Differences and the Ischemia/Bleeding Risk of DAPT Duration","phase":"","overall_status":"UNKNOWN","enrollment_count":16000,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT03945968","title":"The Role of Concomitant Diseases in Postoperative Complications Risk Stratification.","phase":"","overall_status":"RECRUITING","enrollment_count":16000,"lead_sponsor_name":"Russian Federation of Anesthesiologists and Reanimatologists","has_results":false},{"nct_id":"NCT01813435","title":"GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":15991,"lead_sponsor_name":"ECRI bv","has_results":true},{"nct_id":"NCT06565793","title":"A MAajor RAdiation-based PCI Study in STEMI and NSTEMI","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":15630,"lead_sponsor_name":"Centre Cardiologique du Nord","has_results":false},{"nct_id":"NCT07534410","title":"The Prognostic Value of Cardiopulmonary Exercise Testing Parameters in Patients With Coronary Heart Disease: A Retrospective Cohort Study(CPETPCAD)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Xinjiang Medical University","has_results":false},{"nct_id":"NCT05624905","title":"Prospective Pecutaneous Coronary Intervention Registry","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT05888168","title":"Predictors of Postoperative Atrial Fibrillation After CABG","phase":"","overall_status":"UNKNOWN","enrollment_count":15000,"lead_sponsor_name":"Kun Hua","has_results":false},{"nct_id":"NCT04734028","title":"PTRG-DES Consortium","phase":"","overall_status":"COMPLETED","enrollment_count":13160,"lead_sponsor_name":"Gyeongsang National University Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}